Biotech Business - July 2, 2021
Xbrane Biopharma raises 380 million SEK
Xbrane has carried out a directed share issue of SEK 380 millions at a subscription price of SEK 135 per share. The subscription price was determined through an accelerated book-building procedure. A number of Swedish and international institutional investors, including Lancelot Asset Management, Serendipity Group, Swedbank Robur Fonder and TIN Fonder have subscribed for shares […]
Financing - June 29, 2021
SAGA Diagnostics raises 106 million SEK
SAGA Diagnostics has raised SEK 106 million (€10.5 million) in a Series A2 financing from both existing and new investors. The Series A2 round was led by Segulah Medical Acceleration and the Sciety investment syndicate with strong support from existing shareholders such as Hadean Ventures. “We are delighted to complete this oversubscribed financing round with […]
Financing - June 16, 2021
Genetic Analysis awarded 16 million NOK
Genetic Analysis has announced that the Norwegian Research Council has approved its grant application of NOK 16 million for its project developing new innovative microbiome-based diagnostics to be used to aid selection and treatment of IBD patients. “We are pleased to receive this grant from the Norwegian Research Council in supporting our work to improve […]
Financing - June 7, 2021
Alpha Therapy Solutions awarded Eurostars Grant
Swedish radiopharmaceutical production company Alpha Therapy Solutions and Advanced Nuclear Medicine Ingredients S.A., a wholly owned European subsidiary of Telix Pharmaceuticals Limited, have been jointly awarded a 990,000 EUR, a Eurostars-2 research grant from the EUREKA Association. The Eurostars program supports international innovative projects involving at least two different participants from different Eurostars countries and […]
Biotech Business - May 25, 2021
Elicera enters a new development phase
Elicera Therapeutics has announced that the subscription period for the company’s new share issue prior to the planned listing on Nasdaq First North Growth Market began May 24 and runs until June 8. The new share issue consists of a directed issue of a maximum of 6,500,000 Units, each consisting of one (1) new share […]
Financing - April 27, 2021
CardiNor secures NOK 12 million
CardiNor has secured NOK 12 million to commercialize the development of an ELISA test for secretoneurin (SN), a potentially new innovative biomarker for cardiovascular disease. The company will use the funds for CE marking, initiate US regulatory activities and expanding the range of indications, it states in a press release. In addition to existing investors, […]
